SCHEMBL2642360

SCHEMBL2642360

COC(=O)c1cc(S(C)(=O)=O)ccc1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.58
ALDH1A1 P00352 2/20 0.58
HSD17B10 Q99714 2/20 0.58
HPGD P15428 1/20 0.58
LMNA P02545 2/20 0.46
PTGS2 P35354 6/20 0.44
PTGS1 P23219 2/20 0.44
EPAS1 Q99814 1/20 0.43
CA2 P00918 1/20 0.43
KDM4E B2RXH2 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PKM P14618 1/20 0.42
ADRA2A P08913 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
DRD2 P14416 1/20 0.41
DRD3 P35462 1/20 0.41
HTR2B P41595 1/20 0.41
STAT6 P42226 1/20 0.41
KCNH2 Q12809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21709859 0.87 HSD17B10 (0.45) TSHRALDH1A1HSD17B10HPGDLMNA
SCHEMBL3362967 0.85 CA2 (0.58) TSHRALDH1A1HSD17B10HPGDLMNA
SCHEMBL17478992 0.85 ALDH1A1 (0.56) TSHRALDH1A1HSD17B10HPGDLMNA
SCHEMBL20766290 0.84 TSHR (0.55) TSHRALDH1A1HSD17B10HPGDLMNA
SCHEMBL14683630 0.84 TSHR (0.55) TSHRALDH1A1HSD17B10HPGDLMNA
SCHEMBL2642603 0.81 CA2 (0.61) TSHRALDH1A1HSD17B10HPGDLMNA
SCHEMBL2642601 0.81 LMNA (0.47) TSHRALDH1A1HSD17B10LMNAPTGS2
SCHEMBL8350642 0.81 LMNA (0.47) TSHRALDH1A1HSD17B10LMNAPTGS2
SCHEMBL4941551 0.81 PTGS2 (0.48) TSHRALDH1A1HSD17B10HPGDPTGS2
SCHEMBL4935564 0.81 PTGS2 (0.48) TSHRALDH1A1HSD17B10HPGDPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110511173-B Indole alkyl piperazine benzamide compound and application thereof 复旦大学 2023-06-23 CN disclosed
CN-105712952-B 2-substituted oxy-5-methylsulfonyl phenyl piperazine amide analogue and preparation method and application thereof 上海翰森生物医药科技有限公司 2021-03-26 CN disclosed
CN-105712952-A 2-Substituted-phenyl-oxy-5-methylsulfonyl piperazine acidamide analogue and preparation method and application thereof 上海翰森生物医药科技有限公司 2016-06-29 CN disclosed
CN-104211635-A Piperidine compounds, and preparation method, pharmaceutical compositions and use thereof SHANGHAI INST MATERIA MEDICA 2014-12-17 CN disclosed
US-7687502-B2 Substituted quinazoline or pyridopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-03-30 US disclosed
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative MSD K.K. (JP) 2008-02-07 US disclosed
EP-1734040-A1 SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-12-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative GCK, GCKR, PDXK TSHR 2323/4885ALDH1A1 1558/4885HSD17B10 2194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.